<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01874587</url>
  </required_header>
  <id_info>
    <org_study_id>2012-RdC-ORL-Th</org_study_id>
    <secondary_id>2012-A00426-37</secondary_id>
    <nct_id>NCT01874587</nct_id>
  </id_info>
  <brief_title>Adaptative Radiotherapy to Decrease Xerostomia in Oropharynx Carcinoma</brief_title>
  <acronym>ARTIX</acronym>
  <official_title>Phase III Trial Testing the Benefit of Intensity-modulated Radiotherapy With Weekly Replanifications Versus Intensity Modulated Radiotherapy With Only One Planification in Locally Advanced Oropharynx Carcinoma for Decreasing Xerostomia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center Eugene Marquis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Center Eugene Marquis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Phase III study will include 174 patients with locally advanced oropharynx carcinoma,
      receiving all arc-IMRT (Intensity-Modulated Radiation Therapy) (70 Gy) with concomitant
      systemic therapy. Two arc-IMRT treatment arms will be compared: one &quot;standard&quot; arm based on
      the use of a single pre-treatment planning and one &quot;experimental&quot; arm (adaptive RT) based on
      a weekly replanning to spare the salivary glands. The main objective is to increase by 25%
      the salivary flow (Parafilm) 12 months after RT thanks to adaptive RT, while not decreasing
      local control. The secondary objectives are to increase the salivary flow (scintigraphy),
      reduce xerostomia, acute and late toxicities (Eisbruch questionnaire, MDAS-HN, v.4 CTCAE),
      while maintaining local control (stopping rule of the trial if difference&gt;15%). 174 patients
      will be included in 6 French centers for 2 years and followed for 2 years. The HPV (Human
      Papillomavirus) status will be identified and the tumors frozen. A central IMRT QA (Quality
      Assurance) will be performed.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Salivary flow measure</measure>
    <time_frame>12 months after the end of radiotherapy</time_frame>
    <description>The salivary flow is measured after stimulation with Parafilm at the time of inclusion and then 12 months after the end of radiotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Xerostomia</measure>
    <time_frame>From before treatment to 24 months after the end of radiotherapy</time_frame>
    <description>salivary flow measured after stimulation before treatment, 6months, 18 months and 24 months after the end of radiotherapy Eisbruch's questionnaire before treatment, at 3, 6, 12, 18 and 24 months after the end of radiotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Salivary flow</measure>
    <time_frame>Before treatment and 12 months after the end of radiotherapy</time_frame>
    <description>measured by scintigraphy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local control</measure>
    <time_frame>2 years</time_frame>
    <description>analysed according stages T and N, HPV status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early and late toxicities</measure>
    <time_frame>From beginning of the radiotherapy up to 2 years after the end of radiotherapy</time_frame>
    <description>early toxicity : weekly assessment during radiotherapy until 3 months after the end late toxicity : 6, 12, 18 and 24 months after the end of radiotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>2 years</time_frame>
    <description>overall and disease free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Head and Neck functionality</measure>
    <time_frame>Before treatment to 24 months after the end of radiotherapy</time_frame>
    <description>MDASI-HN questionnaire before treatment, 3, 6, 12, 18 and 24 months after the end of radiotherapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">174</enrollment>
  <condition>Oropharynx Cancer</condition>
  <arm_group>
    <arm_group_label>standard radiotherapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>single pre-treatment planning before radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>adaptative radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>adaptive Radiotherapy based on a weekly replanning</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>adaptative radiotherapy</intervention_name>
    <description>weekly replanning</description>
    <arm_group_label>adaptative radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Locally advanced non-metastatic carcinoma of the oropharynx limited to T3 and T4
             (whatever the N) and N2-N3 (whatever the T)(AJCC stage III-IV)

          2. Age ≥ 18 years and ≤ 75 years

          3. Performance status (WHO ≤ 2)

          4. Renal, hepatic and cardiovascular functions allowing systemic treatment administration

          5. Adapted stomatologic care

          6. Signed informed consent form

          7. Membership or beneficiary of a national insurance scheme

        Exclusion Criteria:

          1. Both parotids totally included in the target volume

          2. Stages T1 or T2 with positive node disease N1

          3. Neoadjuvant chemotherapy

          4. Exereses of primitive tumor and/or nodes

          5. History of other cancer within 5 years (except for basocellular epithelioma and
             cervical)

          6. Previous neck radiotherapy

          7. Platinum salts, 5FluoroUracile (5FU) agents or cetuximab chemotherapy considerations

          8. Unstable diseases (cardiovascular, renal, pulmonary, systemic lupus or
             sclerodermia)incompatible with study participation

          9. Patient participating in other therapeutic trial with experimental drug, 30 days
             before the inclusion.

         10. Patient already recruited in another biomedical research ( non interventional study is
             authorized)

         11. Pregnant or breast feeding patients

         12. Patient deprived of liberty, under tutorship, guardianship or placed under judicial
             protection

         13. Patient is deemed incapable of giving informed consent

         14. Patients who, for family, social, geographic or psychological reasons, cannot be
             adequately followed up and/or are incapable of undergoing regular controls.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renaud De Crevoisier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Eugène Marquis - Rennes - France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Renaud De Crevoisier, MD</last_name>
    <phone>+ 33 (0)2 99 25 30 31</phone>
    <email>r.de-crevoisier@rennes.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinique Claude Bernard</name>
      <address>
        <city>Albi</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Auberdiac, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pierre Auberdiac, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur - Saint Esprit</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ali Hasbini, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CRLCC Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Bernard Gery, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CRLCC Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bernard Coche-Dequeant, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal Pommier, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pascal Pommier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CRLCC Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Karen Benezery, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de la Milétrie</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>René-Jean Bensadoun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renaud De Crevoisier, MD</last_name>
      <phone>+33 (0)2 99 25 30 31</phone>
      <email>r.de-crevoisier@rennes.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Renaud De Crevoisier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CRLCC Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sébastien Thureau, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sébastien Thureau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sébastien Guihard</last_name>
    </contact>
    <investigator>
      <last_name>Sébastien Guihard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gilles Calais, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2013</study_first_submitted>
  <study_first_submitted_qc>June 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2013</study_first_posted>
  <last_update_submitted>November 20, 2017</last_update_submitted>
  <last_update_submitted_qc>November 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adaptative radiotherapy</keyword>
  <keyword>oropharynx carcinoma</keyword>
  <keyword>xerostomia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Xerostomia</mesh_term>
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

